In infected cells, EBV can express nine latent growth transformation associated genes, EBNA1-6, LMP1, 2A, 2B and noncoding small RNAs known as EBERs. The latent gene expression varies among different EBV-associated tumors. The BLs express EBERs and EBNA1. This limited expression profile is called latency I. 1 The latency I is also a characteristic of B lymphocytes derived from healthy seropositive subjects. Latency II is defined by expression of EBERs, EBNA1 and LMPs. Under pathological condition, such viral gene expression profile is mainly seen in NPCs and HD. 1 The third form of latency, called latency III is highlighted by expression of all EBV encoded latent proteins. The large polycistronic RNA encoding EBNA 2-6 arise from W or the C promoter. The lymphoblastoid cell lines (LCLs) established by in vitro infection represent this category. AIDS associated immunoblastic lymphomas display latency III.
Host genome methylation is an important regulatory mechanism of eukaryotic gene expression. The methylation-induced silence of Wp and Cp in most EBV associated tumors helps the virus to downregulate its most prominent immunogenic proteins. The demethylating treatment with 5-Aza C confers BL cells a more immunogenic phenotype due to reactivation of Wp-Cp encoded EBNAs. 3, 4 Primary effusion lymphoma (PEL) is a B-cell-derived tumor with nonproductive Ig rearrangement. This tumor arise in body cavities. 2 These cells carry both the human herpesvirus-8 (HHV-8) and EBV. A small subset of PELs, however, lacks EBV. In those cases of PEL, where EBV is also present, the expression of EBV encoded growth transformation proteins is restricted to EBNA1, EBER and LMP2A.
In order to understand the role of EBV in the pathogenesis of PEL, in a previous study, we infected several HHV-8 positive but EBV negative PEL cell lines with a recombinant EBV strain. 5 The converted PELs displayed restricted EBV latency. The lack of EBNA 2-6 in the PEL convertants prompted us to ask if it was due to epigenetic regulation of the viral genome.
HHV-8 pos but EBV neg PEL lines BC-3, CRO-AP/6 and CRO-AP/3 were chosen for this study. 5 Rael and Raji are EBV-positive Burkitt lymphoma cell line. The cells were maintained in RPMI supplemented with 10% FCS and 100 IU of Peniciliin and 100 mg/ml streptomycin. The PELs were subjected to infection with the recombinant EBV as previously described. Exponentially growing BC-3 EBVGFP cl-6, cl-10, CRO-AP/6 EBVGFP cl-1, cl-3 and CRO-APO/3 GFPEBVcl-1 and 2 were seeded at a concentration of 3 Â 10 5 in the complete RPMI medium containing 5 mM 5-Aza C (Sigma), 50 ng/ml TSA (Sigma) or the combination of the two. The treated cells were harvested at 24, 48 and 72 h and live cells were counted at least three times by Trypan blue dye exclusion. The TSA treatment was restricted only for 24 h. As a control, EBV-positive BL line Rael was used which upon demethylation treatment changes its EBV gene expression profile from latency I to latency III. The cytokine treatment was performed on 0.5 Â 10 6 cells/2 ml. The cells were treated with 50 ng/ml IL-4, IL-6 and IL-10 (Peprotech) for 48 h. The expression of EBNA1-6 and LMP1 was verified by immunoblotting. 5 The EBNAs were detected by using a previously characterized polyclonal human serum derived from a seropositive healthy donor. The expression of LMP1 was verified by S12 monoclonal antibody. The chemiluminescence kit (Amersham) was employed to visualize the proteins.
The pattern of EBV latent gene expression in EBV converted PELs has been previously described. 6 As seen in Figure 1 , all three lines when treated with 5-Aza C, TSA or both together, did not express EBNA2. The result was further confirmed by EBNA-2 RT-PCR and immunofluorescence (not shown). The control cell line Rael instead showed upregulation of EBNA2 upon the demethylating treatment. Figure 2 shows expression of LMP1 in treated and untreated parental cells. The induction of LMP1 was observed in all clones examined. For LMP1 induction, in some clones both 5-Aza C and TSA treatment was required. The treatment with TSA þ 5-Aza C for 24 h was sufficient to induce LMP1 but the same treatment did not induce EBNA-2.
Since PELs produces cytokines, which are then used as autocrine growth factors, we asked if these might have any influence on viral latent gene expression. BC-3 GFPEBV cl-6 and cl-10 were treated with IL-4, IL-6 and IL-10. Interestingly, BC-3 cl-6 responded well to IL4 mediated induction of LMP1 expression (Figure 3) . The BC-3 GFPEBV cl-10 did not express LMP1. Both the clones were, however, negative for EBNA-2 expression after cytokine treatment (not shown).
Epigenetic silencing is a widespread mechanism for the control of gene expression. It is thought that viruses have long been taking advantage of this phenomenon to obtain immunological invisibility. EBV genomes are heavily methylated in BLs. In particular, the C and W promoter driven EBNAs are not expressed in BL biopsies due to methylation of these two promoters and treatment of some type I BLs with demethylating agents lead to a shift in EBV gene expression profile to latency III. 7 The question is why PELs cannot express EBNA2-6. Is this a peculiarity of PEL cells or is it due to epigenetic silencing of the viral regulatory regions encoding EBNA2-6? PEL cells are particular from the point of view phenotypic characteristics. They are of B-cell origin but are immunoglobulin nonproducers due to abortive Ig rearrangement. 2 Furthermore, the PELs have a defective B cell transcription factor apparatus. 8 Thus, in spite of the genetic imprint of a B cell, they appear to have lost the B cell identity. In this, PELs closely resemble classical Hodgkin's disease derived cell lines. 6 In terms of EBV latent gene expression as well, the cHD derived lines when infected with EBV cannot express EBNA2-6.
In the present paper, we asked if the lack of expression of EBNA2-6 in PELs could be due to methylation and if so, demethylating treatment with 5-Aza C could lead to activation of EBNA2-6 expression. The findings indicate that observed lack of induction of EBNA2-6 in PELs cannot be attributed to methylation. It is more likely that the lack of transcription factors EBNA expression in 5-Aza C and TSA treated PELs. Total cell lysates were run on SDS-polyacrylamide gel. EBNAs were revealed by using a previously characterized serum from a healthy seropostive donor.
Figure 2
LMP1 expression in 5-Aza C and TSA treated PELs. Total cell lysates were separated on a 7.5% gel by SDS-PAGE. S12 monoclonal antibodies were used to detect LMP1 in PEL EBV convertants. necessary for the Wp or Cp activity could be responsible for the absence of these immunogenic EBNAs. Arguello et al 8 have demonstrated that transfection of Pu.1 and Oct-2 can partially restore the B cell specific transcription program in PELs. The cytokine treatment and in particular, IL-4 and IL-10 was able to induce LMP1 in one EBV infected clone of BC-3. It is known that PELs can secrete these cytokines and that they serve as autocrine growth factors. 10 Our findings that the same cytokines can induce the EBV oncogene LMP1 provide an explanation for the increased tumorigenicity of dually positive PELs in comparison to PELs carrying only HHV-8 observed previously. 5 Both natural and induced shift in the viral latent gene expression, from latency I to III, is seen in BLs. The natural latency shift in most BLs occur after several months of in vitro passage. This is accompanied by a change from a resting B cell phenotype to an immunoblastic phenotype. The hitherto silent Wp/Cp gets activated and EBNA2-6 are expressed. What controls this shift is not known. Whether the expression of EBNA2-6 is the cause or the result of this immunoblastic transformation is also unclear. The natural latency shift resembles the chemically induced shift in that the Wp/Cp activity in latency III expressors is correlated with a demethylating pattern of these regions. 7 In this regard the PELs are unlike BLs. The natural shift in EBV latent gene expression in PELs does not occur even after prolonged in vitro culture, nor is it influenced by demethylating treatment as observed in the present paper. It seems that among B-cell-derived EBV-associated tumors, only immunoblast like cell may have right transcription machinery to express EBNA2-6.
The main interest in the viral latency I to III shift is arguably due to its potential therapeutic applications for EBV associated tumors. Previous studies have shown that chemically induced latency shift makes BLs more immunogenic. 4 Moreover, the therapeutic application of 5-Aza C has been already considered at clinical level without encouraging results. 11 Our results suggest that the regulation of the latency switch is complex. Along with demethylating treatments, the reconstituiton of missing transcription factors machinery will have to be taken into consideration in order to optimize therapies of a wide variety of EBV-related tumors. 
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